Mayank Mamtani

“Just a quick one on, you know, the SOL-20 responses at 36 weeks that you lost about, I think, 9 of 10 patients and then versus the three patients you had deepening, you know, to SOL-10 at 52 weeks or even like I think 11, you had total deepening of responses, best response.”

“A couple of quick questions on the Zafclax. I think you were talking about when failure patients development being explored. Could you maybe just touch on, you know, how quickly you can generate data there?”

“A couple of quick questions on the Zafclax. I think you were talking about when failure patients development being explored. Could you maybe just touch on, you know, how quickly you can generate data there?”

“So, on the shareholder letter, you know, you mentioned the third-party data undercounts VY. Was this curious, Mark, if you could maybe comment on what you're seeing on the total dispense units that, you know, we may not see in IQVIA here?”

“Maybe, Ryan, on the prior point on the OTD MAP-T strategy, are there any genetic thiopathies you could potentially look at and understanding the logic that you're applying to the GLN program?”